Stocks News

LAST PRICE
24.3600
TODAY'S CHANGE (%)
Trending Up1.4300 (6.2364%)

Bid / Lots
24.0100/ 1
Ask / Lots
24.4500/ 5
Open / Previous Close
22.7500 / 22.9300
Day Range
Low 22.5200
High 24.9500
52 Week Range
Low 18.8501
High 49.5000
Volume
1,388,907
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Oct 29, 2024
- Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting, from 6:30AM ET on Tuesday Oct 29, 2024 by Dow Jones
  6:30AM ET on Tuesday Oct 29, 2024 by Dow Jones
  Companies Mentioned: BEAM
  
  Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
  
  CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company's abstracts accepted for presentation at the upcoming 66(th) Annual Meeting of the American Society for Hematology (ASH).
Oct 16, 2024
- Beam Therapeutics Insider Sold Shares Worth $1,342,752, According to a Recent SEC Filing, from 4:47PM ET on Wednesday Oct 16, 2024 by MT Newswires
  4:47PM ET on Wednesday Oct 16, 2024 by MT Newswires
  Companies Mentioned: BEAM
  04:47 PM EDT, 10/16/2024 (MT Newswires) -- Giuseppe Ciaramella, President, on October 14, 2024, sold 51,110 shares in Beam Therapeutics (BEAM) for $1,342,752. Following the Form 4 filing with the SEC, Ciaramella has control over a total of 160,260 s...
- DJ Beam Therapeutics Price Target Announced at $24.00/Share by Scotiabank, from 10:40AM ET on Wednesday Oct 16, 2024 by Dow Jones
  10:40AM ET on Wednesday Oct 16, 2024 by Dow Jones
  Companies Mentioned: BEAM
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/BEAM/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 16, 2024 10:40 ET (14:40 GMT)
- Scotiabank Initiates Beam Therapeutics at Sector Perform With $24 Price Target, from 8:22AM ET on Wednesday Oct 16, 2024 by MT Newswires
  8:22AM ET on Wednesday Oct 16, 2024 by MT Newswires
  Companies Mentioned: BEAM
  08:22 AM EDT, 10/16/2024 (MT Newswires) -- Beam Therapeutics (BEAM) has an average outperform rating and a price target range of $23 to $80, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research fro...

Today
- BioCryst Pharmaceuticals Q3 Loss Narrows, Revenue Rises; 2024 Sales Guidance Issued, from 10 hours ago by MT Newswires
  10 hours ago by MT Newswires
  Companies Mentioned: BCRX
- -- Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Reports Q3 Revenue $117.1M, from 11 hours ago by MT Newswires
  11 hours ago by MT Newswires
  Companies Mentioned: BCRX
- -- Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Posts Q3 Loss $-0.07 Per Share, from 11 hours ago by MT Newswires
  11 hours ago by MT Newswires
  Companies Mentioned: BCRX
- *DJ BioCryst Pharmaceuticals 3Q Loss/Shr 7c >BCRX, from 11 hours ago by Dow Jones
  11 hours ago by Dow Jones
  Companies Mentioned: BCRX
- BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update, from 11 hours ago by Dow Jones
  11 hours ago by Dow Jones
  Companies Mentioned: BCRX
Nov 1, 2024
- DJ Galapagos Is Maintained at Sector Perform by RBC Capital, from 1:17PM ET on Friday Nov 01, 2024 by Dow Jones
  1:17PM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: GLPG
Oct 30, 2024
- *DJ Galapagos 9-Mos Rev EUR200.1M >GLPG.BT, from 4:20PM ET on Wednesday Oct 30, 2024 by Dow Jones
  4:20PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: GLPG
- Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:01PM ET on Wednesday Oct 30, 2024 by Dow Jones
  4:01PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: GLPG
Oct 24, 2024
- BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO(R) (berotralstat), from 8:00AM ET on Thursday Oct 24, 2024 by Dow Jones
  8:00AM ET on Thursday Oct 24, 2024 by Dow Jones
  Companies Mentioned: BCRX
Oct 22, 2024
- Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024, from 8:03AM ET on Tuesday Oct 22, 2024 by Dow Jones
  8:03AM ET on Tuesday Oct 22, 2024 by Dow Jones
  Companies Mentioned: CPRX

Beam Therapeutics Inc
NASDAQ:BEAMUnited States

Search Criteria

Oct 29, 2024

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting, from 6:30AM ET on Tuesday Oct 29, 2024 by Dow Jones

Oct 16, 2024

Beam Therapeutics Insider Sold Shares Worth $1,342,752, According to a Recent SEC Filing, from 4:47PM ET on Wednesday Oct 16, 2024 by MT Newswires

DJ Beam Therapeutics Price Target Announced at $24.00/Share by Scotiabank, from 10:40AM ET on Wednesday Oct 16, 2024 by Dow Jones

Scotiabank Initiates Beam Therapeutics at Sector Perform With $24 Price Target, from 8:22AM ET on Wednesday Oct 16, 2024 by MT Newswires

Peers Headlines

Today

BioCryst Pharmaceuticals Q3 Loss Narrows, Revenue Rises; 2024 Sales Guidance Issued, from 10 hours ago by MT Newswires

-- Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Reports Q3 Revenue $117.1M, from 11 hours ago by MT Newswires

-- Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Posts Q3 Loss $-0.07 Per Share, from 11 hours ago by MT Newswires

*DJ BioCryst Pharmaceuticals 3Q Loss/Shr 7c >BCRX, from 11 hours ago by Dow Jones

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update, from 11 hours ago by Dow Jones

Nov 1, 2024

DJ Galapagos Is Maintained at Sector Perform by RBC Capital, from 1:17PM ET on Friday Nov 01, 2024 by Dow Jones

Oct 30, 2024

*DJ Galapagos 9-Mos Rev EUR200.1M >GLPG.BT, from 4:20PM ET on Wednesday Oct 30, 2024 by Dow Jones

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:01PM ET on Wednesday Oct 30, 2024 by Dow Jones

Oct 24, 2024

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO(R) (berotralstat), from 8:00AM ET on Thursday Oct 24, 2024 by Dow Jones

Oct 22, 2024

Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024, from 8:03AM ET on Tuesday Oct 22, 2024 by Dow Jones